The burgeoning landscape of treatment for excess body fat and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant variations in their pharmacological profiles and clinical trial results are emerging.… Read More

Emerging in the arena of obesity treatment, retatrutide presents a unique strategy. Different from many existing medications, retatrutide functions as a double agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. The concurrent stimulation promotes various helpful effects, such … Read More